gene_symbol
FCGR3A
hgnc_id
HGNC:3619
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Trastuzumab binds HER2 on tumor cells and its Fc engages CD16A on NK cells to trigger ADCC, killing HER2+ tumor cells, not the CD16A-expressing effector cells.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Fc-mediated binding to trigger ADCC
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06446882
disease_id_num_tar_ref
5959
drug_id_num_tar_ref
16160